Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buserelin acetate
Drug ID BADD_D00315
Description Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Indications and Usage Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
Marketing Status Not Available
ATC Code L02AE01
DrugBank ID DB06719
KEGG ID D01831
MeSH ID D002064
PubChem ID 50224
TTD Drug ID D04GSY
NDC Product Code 71052-358
Synonyms Buserelin | Buserelin Acetate | Acetate, Buserelin | Suprefact | Profact | Receptal | Tiloryth | Suprecur | Bigonist | HOE-766 | HOE 766 | HOE766
Chemical Information
Molecular Formula C62H90N16O15
CAS Registry Number 68630-75-1
SMILES CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=C C=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC( =O)N6.CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Tumour pain16.32.03.003--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Vulvovaginal discomfort21.08.02.005--Not Available
Vulvovaginal dryness21.08.02.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Withdrawal bleed21.01.01.010; 08.06.02.005--Not Available
Hypoacusis04.02.01.006--
Onychoclasis23.02.05.005--Not Available
Osteopenia15.02.03.003; 14.04.04.004--Not Available
Feminisation acquired21.10.04.004; 05.05.02.007--
Lymphatic disorder01.09.01.003--Not Available
Nasal discomfort22.02.05.020--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages